Vaccine News and Research

Latest Vaccine News and Research

Flu-fighting proteins found in human cells stop flu virus, uncover scientists

In findings that may lead to better ways to prevent and treat influenza and other viral infections, researchers report the discovery of a family of naturally occurring antiviral agents in human cells.

18 Dec 2009

Comprehensive approaches to understand the interaction of H1N1 strains with human cells

Scientists have generated hundreds of new leads in the fight against the H1N1 flu pandemic, according to two new studies published online December 17th in the journal Cell, a Cell Press publication.

18 Dec 2009

Duane Reade offers H1N1 immunization vaccines for New York residents

Duane Reade, the largest drug store chain in New York City, today announced plans for its H1N1 immunization program as part of the Company's commitment to meet the health and wellness needs of New Yorkers and to be a destination for their flu related needs.

18 Dec 2009

Also in Global Health news: Hospital births in Guinea-Bissau; drought in E. Africa; drug-resistant malaria; U.S. response to H1N1

IRIN examines the increase in the number of women giving birth in hospital settings rather than delivery by a traditional birth attendant - a behavior that health officials hope will lead to a drop in the country's maternal mortality rate. "According to UNFPA, 38 percent of women gave birth in a hospital in 2009, up from 29 percent in 2003," the news service writes.

17 Dec 2009

La Jolla Institute for Allergy & Immunology awarded $18.8M NIH grant for infectious diseases study

Researchers from the La Jolla Institute for Allergy & Immunology will take aim at several of the world's most dangerous infectious diseases - tuberculosis, malaria and dengue virus -- in a five-year, $18.8 million federally-funded set of projects seeking to make new inroads toward vaccines against the disorders.

17 Dec 2009

African AIDS vaccine conference addresses future trials in Africa, lower participation rates among women

During the Forum of the African AIDS Vaccine Program (AAVP) in Kampala, Uganda, on Wednesday, Alan Bernstein, the director of the Global HIV Vaccine Enterprise, discussed ongoing efforts to launch an experimental HIV vaccine trial - similar to the recent trial in Thailand - in Africa, the Daily Monitor reports.

17 Dec 2009

Promising breakthrough in adjuvant development may lead to cost-effective therapeutic vaccines

It should be possible to use therapeutic vaccines to create both cheap and effective drugs for diseases like cancer and allergies. One problem in developing such vaccines has previously been the lack of adjuvants, substances that make vaccines more effective. However, there has now been a major breakthrough in this area. The study, led by Swedish scientists at Uppsala University, is published in the December issue of the journal Vaccine.

17 Dec 2009

Three H1N1 influenza vaccination clinics scheduled to offer vaccines free of charge

2010 is just over two weeks away. Make a New Year's resolution for you and your family members and start the new year out right by getting your H1N1 influenza shot at one of the available clinics in southeast Michigan.

17 Dec 2009

Health Research Institute presents top 10 issues in the upcoming year

PricewaterhouseCoopers' Health Research Institute's Top 10 Health Industry Issues in 2010, puts healthcare cost control at the head of the list as the overarching theme for the year ahead.

17 Dec 2009

Sanofi Pasteur uses PHT’s LogPad System and StudyWorks online portal for its Phase II trial

PHT Corporation announced that Sanofi Pasteur is using PHT’s LogPad® System and StudyWorksTM online portal for a Phase II trial to develop a vaccine against the Clostridium difficile bacterium.

17 Dec 2009

Infection control program protects immunocompromised cancer patients from H1N1 infection

Despite a 100-fold increase in H1N1 influenza cases in the Seattle area during spring 2009, an aggressive infection control program to protect immunocompromised cancer patients and thorough screening measures resulted in no corresponding increase in H1N1 cases among the total patient population at the Seattle Cancer Care Alliance, according to a new study by researchers and physicians at Fred Hutchinson Cancer Research Center and the SCCA.

17 Dec 2009

New licensing agreement to develop and commercialize prophylactic vaccine against MRSA signed

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that it has entered into an exclusive, world-wide licensing agreement with Syntiron to develop and commercialize its prophylactic vaccine against Staphylococcus, including Methicillin-Resistant Staphylococcus aureus or MRSA.

17 Dec 2009

Thermo Fisher Scientific selected as NCS biological and environmental sample repository partner

Thermo Fisher Scientific Inc., the world leader in serving science, today announced it has been selected as the National Children’s Study (NCS) biological and environmental sample repository partner. The study examines the effects of environmental influences on the health and development of 100,000 children across the United States, following them from before birth until age 21.

From Thermo Fisher Scientific Inc. 17 Dec 2009

Survey examines disease R&D investment in 2008

According to an annual survey released Tuesday by the George Institute for International Health that looks at research and development (R&D) funding of diseases that affect the developing world, the U.S. government in 2008 "remained the single biggest contributor as it again provided almost half of the total funding but the report notes developing countries like Brazil [and] India ... were becoming a growing force," AAP/Sydney Morning Herald reports (Rose, 12/15).

17 Dec 2009

Scientists draw on bacterial decision-making success to guide human choices on H1N1 vaccine

Bacteria inhabited our planet for more than 4 billion years before humans showed up, and they'll probably outlive us by as many eons more. That suggests they may have something to teach us.

17 Dec 2009

Opinions: HIV prevention; PEPFAR; H1N1 vaccine donation; developing country R&D; climate change

"For nearly 30 years scientists have been trying to break the back of the AIDS epidemic," but the recent microbicide gel study and an AIDS vaccine trial in Thailand "show just how difficult and how distant that goal is," according to a Washington Post editorial. "While scientists continue searching for a vaccine or a cure, prevention remains paramount," the Washington Post concludes (12/16).

16 Dec 2009

New study to evaluate the effectiveness of H1N1 and seasonal flu vaccines in pregnant women conducted

Abt Associates will conduct a study for the Centers for Disease Control and Prevention (CDC) to evaluate the effectiveness of the H1N1 and seasonal flu vaccines among pregnant women, one of the high risk populations identified by CDC.

16 Dec 2009

WHO using new bivalent oral polio vaccine in Afghanistan

The WHO on Tuesday launched a vaccination campaign in Afghanistan that will use "a new and more effective polio vaccine" for the first time, Reuters reports (Nebehay, 12/15).

16 Dec 2009

Syntiron grants sanofi pasteur exclusive world-wide license to its human vaccine against MRSA

Syntiron today announced that it has granted sanofi pasteur an exclusive world-wide license to its human vaccine against Staphylococcus aureus. The agreement includes an undisclosed initial licensing fee, milestone payments and royalty payments on future sales of the product. Staphylococcus aureus, or MRSA (pronounced Mer-sa) is an important hospital-acquired infection and is a major cause of illness and death resulting in excess of 18,000 US deaths a year and a half million hospitalizations, creating a significant economic burden of approximately $3.4 billion annually to the American health care system.

16 Dec 2009

Advanced Life Sciences Holdings' Restanza promising against tularemia

Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), today announced positive top-line results from a pivotal, non-human primate study of its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin) against an inhaled lethal dose of tularemia. A 14-day course of Restanza achieved a 100% survival rate at the doses tested. All of the ten animals in the study that received 16 mg/kg once-a-day of Restanza (approximate to a human dose of 300 mg) within 24 hours after exposure to a lethal dose of inhaled tularemia survived while only one of the ten animals that received placebo survived.

16 Dec 2009

Vaccine News and Research

Latest Vaccine News and Research

Flu-fighting proteins found in human cells stop flu virus, uncover scientists

Comprehensive approaches to understand the interaction of H1N1 strains with human cells

Duane Reade offers H1N1 immunization vaccines for New York residents

Also in Global Health news: Hospital births in Guinea-Bissau; drought in E. Africa; drug-resistant malaria; U.S. response to H1N1

La Jolla Institute for Allergy & Immunology awarded $18.8M NIH grant for infectious diseases study

African AIDS vaccine conference addresses future trials in Africa, lower participation rates among women

Promising breakthrough in adjuvant development may lead to cost-effective therapeutic vaccines

Three H1N1 influenza vaccination clinics scheduled to offer vaccines free of charge

Health Research Institute presents top 10 issues in the upcoming year

Sanofi Pasteur uses PHT’s LogPad System and StudyWorks online portal for its Phase II trial

Infection control program protects immunocompromised cancer patients from H1N1 infection

New licensing agreement to develop and commercialize prophylactic vaccine against MRSA signed

Thermo Fisher Scientific selected as NCS biological and environmental sample repository partner

Survey examines disease R&D investment in 2008

Scientists draw on bacterial decision-making success to guide human choices on H1N1 vaccine

Opinions: HIV prevention; PEPFAR; H1N1 vaccine donation; developing country R&D; climate change

New study to evaluate the effectiveness of H1N1 and seasonal flu vaccines in pregnant women conducted

WHO using new bivalent oral polio vaccine in Afghanistan

Syntiron grants sanofi pasteur exclusive world-wide license to its human vaccine against MRSA

Advanced Life Sciences Holdings' Restanza promising against tularemia

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Vaccine News and Research

Latest Vaccine News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in